Altmetric

Association between low-grade inflammation and Breast cancer and B-cell Myeloma and Non-Hodgkin Lymphoma: findings from two prospective cohorts

File Description SizeFormat 
s41598-018-29041-1.pdfPublished version1.11 MBAdobe PDFView/Open
Title: Association between low-grade inflammation and Breast cancer and B-cell Myeloma and Non-Hodgkin Lymphoma: findings from two prospective cohorts
Authors: Berger, E
Delpierre, C
Hosnijeh, FS
Kelly-Irving, M
Portengen, L
Bergdahl, IA
Johansson, A-S
Krogh, V
Palli, D
Panico, S
Sacerdote, C
Tumino, R
Kyrtopoulos, SA
Vineis, P
Chadeau-Hyam, M
Vermeulen, R
Castagne, R
Item Type: Journal Article
Abstract: Chronic inflammation may be involved in cancer development and progression. Using 28 inflammatory-related proteins collected from prospective blood samples from two case-control studies nested in the Italian component of the European Prospective Investigation into Cancer and nutrition (n = 261) and in the Northern Sweden Health and Disease Study (n = 402), we tested the hypothesis that an inflammatory score is associated with breast cancer (BC) and Β-cell Non-Hodgkin Lymphoma (B-cell NHL, including 68 multiple myeloma cases) onset. We modelled the relationship between this inflammatory score and the two cancers studied: (BC and B-cell NHL) using generalised linear models, and assessed, through adjustments the role of behaviours and lifestyle factors. Analyses were performed by cancer types pooling both populations, and stratified by cohorts, and time to diagnosis. Our results suggested a lower inflammatory score in B-cell NHL cases (β = −1.28, p = 0.012), and, to lesser, extent with BC (β = −0.96, p = 0.33) compared to controls, mainly driven by cancer cases diagnosed less than 6 years after enrolment. These associations were not affected by subsequent adjustments for potential intermediate confounders, notably behaviours. Sensitivity analyses indicated that our findings were not affected by the way the inflammatory score was calculated. These observations call for further studies involving larger populations, larger variety of cancer types and repeated measures of larger panel of inflammatory markers.
Issue Date: 17-Jul-2018
Date of Acceptance: 4-Jul-2018
URI: http://hdl.handle.net/10044/1/62016
DOI: https://dx.doi.org/10.1038/s41598-018-29041-1
ISSN: 2045-2322
Publisher: Nature Publishing Group
Journal / Book Title: Scientific Reports
Volume: 8
Issue: 1
Copyright Statement: © 2018 The Author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Sponsor/Funder: Commission of the European Communities
Funder's Grant Number: 226756
Keywords: Science & Technology
Multidisciplinary Sciences
Science & Technology - Other Topics
C-REACTIVE PROTEIN
GENERAL-POPULATION
SOLUBLE CD30
FUTURE RISK
FACTOR-I
MARKERS
CYTOKINES
SERUM
BIOMARKERS
IMMUNE
EnviroGenoMarkers
Publication Status: Published
Article Number: 10805
Online Publication Date: 2018-07-17
Appears in Collections:Division of Surgery
Division of Cancer
Faculty of Medicine
Epidemiology, Public Health and Primary Care



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx